INGRAM-MICRO-CLOUD
Ingram Micro Cloud today announced that it is now distributing a full range of Amazon Web Services, Inc. (AWS) products and services to its reseller network in Hungary and Poland. The move bolsters the global offering of Ingram Micro’s Cloud Marketplace, one of the world’s most comprehensive and broadly adopted set of cloud solutions.
Ingram Micro Cloud, an AWS Advanced Consulting Partner and AWS Distributor, announced its global Strategic Collaboration Agreement (SCA) with AWS in March this year. One of the central objectives of the agreement between the business leaders is extending the global reach and footprint of AWS and its partners. As part of this global expansion, Ingram Micro Cloud is now delivering a complete portfolio of AWS solutions to resellers in Hungary and Poland, in addition to its recent launches in France, Mexico, Australia, and New Zealand, which were part of a series of authorizations in 2021. As a result of the SCA with AWS, Ingram Micro expects its large network of partners to see new opportunities to meet customer needs and expand their infrastructure as a service (IaaS) business.
"The distribution alliance between Ingram Micro Cloud and AWS in our region is a great strategic milestone for us,” said Attila Virágh, Managing Director at Ingram Micro Hungary. “Teaming further with AWS brings tremendous opportunity and additional business value to our channel partners within the cloud ecosystem by helping them execute at scale, and quickly meet the business needs of their customers.”
“I’m happy to see AWS joining our marketplace offering in Central and Eastern Europe. I am confident this relationship will significantly contribute to the acceleration of as-a-service models and customers’ cloud migration,” said Jacek Jedraszka, Managing Director at Ingram Micro Poland.
AWS and Ingram Micro Cloud are working together to bolster Ingram Micro Cloud’s current skills and offerings, as well as develop new resources to support channel partners in managing end customers. Ingram Micro Cloud currently provides an AWS Cloud Center of Excellence (CCoE) team with 200+ AWS Certifications, AWS Professional Services, AWS Managed Services, AWS Well-Architected Services, AWS Operations and Billing Services, and more.
Ingram Micro Cloud also covers a wide range of partner enablement and support initiatives to help AWS Partners build an AWS practice through its partner programs, which provide end-to-end engagement models for Ingram Micro Cloud to enable systems integrators (SIs) and independent software vendors (ISVs) in their journey on the cloud.
“We are pleased to differentiate our broad portfolio of cloud services with the addition of AWS on our Cloud Marketplace,” said Nora Papp, Head of Cloud for Central and Eastern Europe at Ingram Micro. “Through this important expansion of pioneering solutions and services, Ingram Micro Cloud is offering our reseller partners the seamless capability to build a successful AWS practice and deliver greater value to their customers.”
Further information about Ingram Micro Cloud’s AWS offerings can be found here .
About Ingram Micro Cloud
Ingram Micro Cloud brings together innovators and problem solvers to help the world accomplish more. It facilitates and manages the cloud’s complex digital value chain—all powered by CloudBlue technology. Ingram Micro Cloud operates in 76 countries with over 55,000 reseller partners, and its Cloud Marketplace serves 17.2 million seats, offering more than 120 cloud solutions. With unmatched global reach, easy access to automated go-to-market and integration tools, deep technical expertise, and a curated selection of scalable SaaS and IaaS solutions, Ingram Micro Cloud helps vendors, resellers and managed service providers by offering More as a Service. Detailed information is available at www.IngramMicroCloud.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom